Abstract
As both humans and fungi are eukaryotic organisms, antifungal agents affect their cellular metabolism. Thus, a relatively few antifungals with minimal toxicity and side-effects are available compared with a plethora of antibacterials. These agents currently prescribed in dentistry belong to two major groups, the polyenes (nystatin and amphotericin B) and the azoles (imidazoles and triazoles). A newly recognized phenomenon known as the post-antifungal effect implies that antifungals, even at sub-therapeutic concentrations, may suppress the virulent attributes of yeasts, especially intra-orally where topical drug levels fluctuate dramatically during dosing intervals.
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / adverse effects
-
Antifungal Agents / classification
-
Antifungal Agents / therapeutic use*
-
Candida / drug effects
-
Candida / growth & development
-
Candida / pathogenicity
-
Candidiasis, Oral / drug therapy*
-
Clotrimazole / administration & dosage
-
Clotrimazole / therapeutic use
-
Drug Interactions
-
Drug Resistance, Microbial
-
Fluconazole / administration & dosage
-
Fluconazole / therapeutic use
-
Humans
-
Itraconazole / administration & dosage
-
Itraconazole / therapeutic use
-
Ketoconazole / administration & dosage
-
Ketoconazole / therapeutic use
-
Miconazole / administration & dosage
-
Miconazole / therapeutic use
-
Nystatin / administration & dosage
-
Nystatin / therapeutic use
-
Virulence / drug effects
Substances
-
Antifungal Agents
-
Nystatin
-
Itraconazole
-
Miconazole
-
Amphotericin B
-
Fluconazole
-
Clotrimazole
-
Ketoconazole